Distrubances of bone tissue metabolism
Conditions
Interventions
Intravnous alendoronate group: Intravenous administration of 100 ml of alendronate at once per month. One course is one month and this treatment is continued 12 courses.
Jelly alendronate group: A
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged more than 20 years . 2. Patients with osteoporosis diagnozed by DXA method (definition of osteoporosis: YAM value is under 80 %) 3. Patients underwent gastrectomy 4. Patients with bone fracture or YAM value is under -1.5SD. 5. Patients without treatments for malignancies 6. Patients without past history of invasive dental treatments within 3 months 7. Patients who gaved informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with some diseaes which may be worse by the participation of this study. 2. Pregnant patients or patients who hope pregnancy 3. Patients who are judged inappropriate by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density (L1-4) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Bone mineral density of the total hip 2. Bone turnover markers (serum BAP, serum NTx, Serum TPACP-5b) 3. Adverse effect | — |
Countries
Japan
Contacts
Public ContactHirochika Makino
Gastroenterological Center Gastroenterological Center
Outcome results
None listed